DESIPRAMINE
Constipation
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Small moleculePhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the Constipation cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
N-Methylnaltrexone Bromide Bausch Health Americas, Inc. | Phase 3 | BB |
Lubiprostone University of Rochester | Phase 4 | BB |
Moa-728 Bausch Health Americas, Inc. | Phase 2 | BB |
Oxycodone Mundipharma Research GmbH & Co KG | Phase 3 | BB |
17-ALLYL-4,5A-EPOXY-3,14-DIHYDROXYMORPHINAN-6-ONE Mundipharma Research GmbH & Co KG | Phase 3 | BB |
View all 28 →
Same molecule, other indications
DESIPRAMINE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →